Expand Biosimilar Oncology Portfolio - Biocon Ltd

Code BSE: 532523 NSE:

Biocon Biologics to Expand Biosimilar Oncology Portfolio, Outline Strategic Vision at the 2026 J.P. Morgan Healthcare Conference a) New oncology assets to include proposed biosimilars for Trastuzumab/Hyaluronidase combination (Herceptin SC/Herceptin HYLECTA), Nivolumab (Opdivo®) and Pembrolizumab (Keytruda) b) Company to outline integration as a wholly owned subsidiary into Biocon Ltd., strengthening its global leadership in biosimilar insulins and GLP-1 peptide generics to cover the full spectrum of diabetes care